The 5th Lipid Nanoparticles Development Summit Europe returns to Berlin, 23^rd – 24^th  September 2026, as the leading meeting for advancing LNP-enabled gene therapy delivery. Bringing together experts from BioNTech, AstraZeneca, Johnson & Johnson, Sanofi and AbbVie, the summit covers end-to-end LNP development, from formulation through to analytics, CMC and scalable manufacturing. Attendees will explore solutions to overcome liver tropism, enable extrahepatic delivery and engineer next-generation nanoparticle systems across mRNA, DNA and gene editing therapies. With interactive discussions and real-world case studies, this event delivers actionable insights to accelerate safe, targeted and clinically viable delivery platforms.

To learn more and register online, please visit: https://ter.li/mft1fbw0